Butantan should release data on the effectiveness of CoronaVac on Wednesday (23) and apply for registration in Anvisa | National newspaper

In the external committee of the Chamber of Deputies, which monitors actions against Covid, the president of Fiocruz delivered a schedule on the arrival of the AstraZeneca vaccine, developed in partnership with the University of Oxford, and on the availability of doses for the National Program. Vaccines, PNI.

“The great anguish of our society is in relation to the start of vaccination. So, I just inform everyone that, in the case of Fiocruz, we will be receiving active pharmaceutical ingredients for the start of production in January. We will be delivering from the week of February 8 the doses of the vaccine that will be the Covid / Fiocruz vaccine. This is our delivery schedule, from that week of February, from 8 to 12, we will be delivering a million doses of vaccines to the PNI “, explained Nísia Trindade Lima, president of Fiocruz.

Fiocruz’s goal is to produce 700,000 daily doses.

In the same commission, the Minister of Health said that there will be a vaccine at the end of February. “Our forecast, as always, is late January at best, through mid-February, late February at worst. We are going strong to be able to have vaccines of various shades and deliver as quickly as possible, ”said Eduardo Pazuello. , Health Minister.

The Ministry of Health foresees, in the first half of 2021, 150 million doses of vaccines added to the doses of the AstraZeneca vaccine; CoronaVac, Sinovac in partnership with Instituto Butantan; and Pfizer / BioNTech.

Anvisa’s technical team, who traveled to China, certified Sinovac for good manufacturing practices for the pharmaceutical ingredient to be used in the vaccine. Anvisa affirmed that the certification of the factory was advanced about ten days in relation to the initial forecast, and that the stage now concluded “is part of the agency’s continuous effort to make vaccines available to the population with quality, safety and efficacy. in the shortest time. ” possible”.

The Butantan Institute announced that the third and final phase of the CoronaVac vaccine clinical trials has been completed. The institute received three more shipments of doses and is expected to end 2020 with a stock of 10.8 million prepared doses.

This Wednesday (23) will be a decisive day: Butantan will release information on the effectiveness of CoronaVac and must request the definitive registration and also the emergency use, this second with approval from Anvisa in up to ten days. Sinovac is also expected to submit a request to the Chinese watchdog agency on Wednesday.